Akili Interactive describes itself as a “prescription digital medicine company providing the first-and-only prescription treatment delivered through video games”. The company is most well known for earning regulatory clearance from the FDA for the first video-game-based therapy to treat children with ADHD. Akili just announced they will now be using the same technology (EndeavorRX, formerly called Project EVO) to test if its software can help adults suffering from Covid “brain fog.”
More than 100 million people across the globe have been infected with COVID-19. Evidence is mounting on long-term neurological and cognitive symptoms that can persist in some COVID-19 patients, including after the virus is no longer detected in the body.
Two randomized remote studies, one conducted by Weill Cornell Medicine and NewYork-Presbyterian Hospital and the other by Vanderbilt University Medical Center, will assess whether AKL-T01, the treatment that Akili commercially markets for ADHD as EndeavorRx, can help improve cognition symptoms in Covid survivors.
